Glaucoma News and Research RSS Feed - Glaucoma News and Research

While there are many causes of glaucoma, most cases are associated with increased intraocular pressure. Loss of vision is usually characterized by a gradual reduction in peripheral vision, which can lead to a tunnel vision effect. Glaucoma affects approximately 100 million people globally and is one of the leading causes of blindness in the world today. An estimated three million Americans have this sight-threatening disease. Because it is painless and advances gradually, many people who have glaucoma or elevated IOP have not been diagnosed. If detected and treated early, vision can usually be preserved.
Study shows correlation between education and nearsightedness

Study shows correlation between education and nearsightedness

Education and behavior have a greater impact on the development of nearsightedness than do genetic factors: With each school year completed, a person becomes more nearsighted. [More]
Acute glaucoma is largely an inflammatory disease, say researchers

Acute glaucoma is largely an inflammatory disease, say researchers

Researchers at the University of California, San Diego School of Medicine and Sun Yat-sen University in China have shown that acute glaucoma in mice is largely an inflammatory disease and that high pressure in the eye causes vision loss by setting in motion an inflammatory response similar to that evoked by bacterial infections. [More]
BrightFocus offers grants to 55 scientists for Alzheimer's disease and vision research

BrightFocus offers grants to 55 scientists for Alzheimer's disease and vision research

BrightFocus Foundation, a nonprofit organization funding cutting-edge, innovative research on Alzheimer's disease and the vision diseases of glaucoma and macular degeneration, today announced the recipients of new research grant awards, offered to 55 scientists in 19 U.S. states, the District of Columbia, and five foreign countries. [More]
Quantel Medical receives FDA clearance for Optimis Fusion integrated laser platform

Quantel Medical receives FDA clearance for Optimis Fusion integrated laser platform

Quantel Medical today announced FDA 510(k) clearance for its Optimis Fusion integrated laser platform. The Optimis Fusion system combines advanced selective laser trabeculoplasty (SLT) photoregeneration therapy and traditional YAG photodisruption treatments to offer ophthalmologists a versatile armamentarium for treating both cataract and glaucoma in an efficient combination platform. [More]
Integrated therapies can reduce depression by half among people with low vision due to AMD

Integrated therapies can reduce depression by half among people with low vision due to AMD

The first clinical trial to examine integrated low vision and mental health treatment has shown that the approach can reduce the incidence of depression by half among people with low vision due to age-related macular degeneration (AMD). [More]
Dental pulp stem cells can protect retinal ganglion cells from death following injury

Dental pulp stem cells can protect retinal ganglion cells from death following injury

Researchers at the University of Birmingham, UK, led by Dr. Ben Scheven, Dr. Wendy Leadbeater and Ben Mead have discovered that stem cells isolated from the teeth, termed dental pulp stem cells (DPSC), can protect retinal ganglion cells (RGCs) from death following injury and promote regeneration of their axons along the optic nerve. [More]
Researchers find unique cell type that can protect against uveitis

Researchers find unique cell type that can protect against uveitis

Researchers at the National Eye Institute (NEI) have found a unique cell type that, in tests on mice, can protect against uveitis—a group of inflammatory diseases that affect the eye and can cause vision loss. [More]
BioLight enrolls first patient in FDA Phase 1/2a clinical trial with Eye-D for treatment of glaucoma

BioLight enrolls first patient in FDA Phase 1/2a clinical trial with Eye-D for treatment of glaucoma

BioLight Israeli Life Sciences Investments Ltd., a firm that invests in, manages and commercializes biomedical innovations grouped into clusters around defined medical conditions, announces that the first patient has been enrolled in the U.S. into a FDA Phase 1/2a clinical trial with Eye-D, the company's controlled-release latanoprost insert for the treatment of glaucoma. [More]
American Academy of Ophthalmology does not recommend marijuana for glaucoma treatment

American Academy of Ophthalmology does not recommend marijuana for glaucoma treatment

The American Academy of Ophthalmology – the world's largest association of eye physicians and surgeons – is reminding the public that it does not recommend marijuana or other cannabis products for the treatment of glaucoma. [More]
Study links nearsightedness to higher education and years spent in school

Study links nearsightedness to higher education and years spent in school

German researchers have found strong evidence that attaining a higher level of education and spending more years in school are two factors associated with a greater prevalence and severity of nearsightedness, or myopia. [More]

Aerie Pharmaceuticals' Roclatan meets all clinical endpoints in Phase 2b trial

Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today reported the successful results of its Phase 2b trial for once-daily, quadruple-action RoclatanTM, a combination of Aerie's triple-action RhopressaTM with latanoprost, a prostaglandin analogue (PGA). [More]
Italian Medicines Agency grants marketing authorization to ILUVIEN for chronic DME treatment

Italian Medicines Agency grants marketing authorization to ILUVIEN for chronic DME treatment

pSivida Corp., a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the Italian Medicines Agency (Agenzia Italiana del Farmaco) has granted marketing authorization to ILUVIEN for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies. [More]
Alternative disposal process in optic nerve cells has implications for neurodegenerative diseases

Alternative disposal process in optic nerve cells has implications for neurodegenerative diseases

Biologists have long considered cells to function like self-cleaning ovens, chewing up and recycling their own worn out parts as needed. [More]
Nicox launches expanded access to Sequenom Laboratories' RetnaGene portfolio

Nicox launches expanded access to Sequenom Laboratories' RetnaGene portfolio

Nicox S.A., the international ophthalmic company, and Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced that Nicox's subsidiary, Nicox Inc. is launching expanded access to Sequenom Laboratories' RetnaGene™ portfolio of laboratory-developed genetic tests in the United States (U.S.). [More]
University Hospitals introduces surgical procedure for management of glaucoma in NE Ohio

University Hospitals introduces surgical procedure for management of glaucoma in NE Ohio

With the arrival of a leading expert in glaucoma, Douglas Rhee, MD, as its chairman of the Department of Ophthalmology and Visual Sciences, University Hospitals Case Medical Center is introducing a surgical procedure for the management of glaucoma that is new to Northeast Ohio. [More]

Glaucoma can affect both infants and adults

When Christian Earl was six weeks old, his mother did not think his eyes looked right, so she took him to Loyola University Medical Center for an evaluation. [More]
New study on transmitophagy process may help treat diverse disorders

New study on transmitophagy process may help treat diverse disorders

It's broadly assumed that cells degrade and recycle their own old or damaged organelles, but researchers at University of California, San Diego School of Medicine, The Johns Hopkins University School of Medicine and Kennedy Krieger Institute have discovered that some neurons transfer unwanted mitochondria - the tiny power plants inside cells - to supporting glial cells called astrocytes for disposal. [More]

Low-power sensor to track changes in eye pressure for management of glaucoma

Your eye could someday house its own high-tech information center, tracking important changes and letting you know when it's time to see an eye doctor. [More]

Simulator for evaluating effects of visual impairment on person's driving performance

The University of California, San Diego School of Medicine is the first ophthalmology department in the nation to feature a fully dedicated high-fidelity, highly realistic driving simulator for evaluating the effects of visual impairment on a person's driving performance. [More]
Celsus’ expert highlights serious side effects of topical corticosteroids

Celsus’ expert highlights serious side effects of topical corticosteroids

A 2013 Mayo Clinic study involving more than 140,000 patients revealed that skin disorders are the most common nonacute reason Americans seek health care. [More]